会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 76. 发明授权
    • Formulation of silibinin with high efficacy and prolonged action and the preparation method thereof
    • 具有高效和长效作用的水飞蓟宾制剂及其制备方法
    • US09023388B2
    • 2015-05-05
    • US13126251
    • 2009-11-23
    • Ximing XuJiangnan YuXia CaoYuan Zhu
    • Ximing XuJiangnan YuXia CaoYuan Zhu
    • A61K31/357B29C35/16B82Y5/00B82Y40/00A61K9/16A61K9/20A61K9/48
    • A61K31/357A61K9/1617A61K9/1635A61K9/1652A61K9/2027A61K9/2054A61K9/2068A61K9/2095A61K9/4866A61K9/4875Y10S977/773Y10S977/888Y10S977/906
    • A high-efficacy, long-acting formulation of silibinin, comprising silibinin solid dispersion, silibinin-loaded silica nanoparticles, slow-release matrix material and release enhancer, wherein the mass ratio of these components is silibinin solid dispersion:silibinin-loaded silica nanoparticles:slow-release matrix material:release enhancer=1:0.5˜1.25:0.1˜0.3:0.1˜0.3; the drug loading rate of the said silibinin-loaded silica nanoparticles is 51.29˜51.77%; the said silibinin solid dispersion contains povidone K30, soybean lecithin, acrylic resin IV, wherein the mass ratio between silibinin and other medical accessories is silibinin:povidone K30:soybean lecithin:acrylic resin IV=1:1˜3:0.3˜0.8:0.2˜0.5. Compared with the existing formulations, the half life of the high-efficacy, long-acting formulation of silibinin disclosed in this invention is 14.8 times longer while the mean residence time (MRT) of which is 4.52 times longer; when tested in vivo in Beagle dogs, this new formulation of silibinin presents a smoother concentration-time curve and reaches the continuous release for 72 hours. This invention discloses its preparation method.
    • 含有水飞蓟宾固体分散体,含有载脂蛋白的二氧化硅纳米粒子,缓释基质材料和释放增强剂的高效长效制剂,其中这些组分的质量比为硅胶蛋白固体分散体:载有载脂蛋白的二氧化硅纳米粒子: 缓释基质材料:释放增强剂= 1:0.5〜1.25:0.1〜0.3:0.1〜0.3; 所述含有载脂蛋白的二氧化硅纳米粒子的药物加载速率为51.29〜51.77%; 所述的水飞蓟宾固体分散体含有聚维酮K30,大豆卵磷脂,丙烯酸树脂IV,其中水飞蓟宾与其他医用附件之间的质量比为硅胶蛋白:聚维酮K30:大豆卵磷脂:丙烯酸树脂IV = 1:1〜3:0.3〜0.8:0.2 ~0.5。 与现有制剂相比,本发明公开的高效,长效制剂的水飞蓟宾的半衰期为14.8倍,平均停留时间(MRT)为4.52倍; 当在Beagle犬体内进行体内测试时,这种新的配制的水飞蓟宾提供更平滑的浓度 - 时间曲线并达到连续释放72小时。 本发明公开了其制备方法。